1. FC 124: Real-World Use of Once-Weekly Semaglutide by Baseline Estimated Glomerular Filtration Rate—A Post-Hoc Analysis of Pooled Data From the Sure Studies (Canada, Denmark/Sweden, Switzerland and UK). (3rd May 2022) Authors: Rudofsky, Gottfried; Catarig, Andrei-Mircea; Erhan, Umut; Jain, Rashmi; Tang Knudsen, Søren; Saravanan, Ponnusamy; Yale, Jean-François Journal: Nephrology dialysis transplantation Issue: Volume 37(2022)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. Issue 2 (5th April 2022) Authors: Yale, Jean-François; Bodholdt, Ulrik; Catarig, Andrei-Mircea; Catrina, Sergiu; Clark, Alice; Ekberg, Neda Rajamand; Erhan, Umut; Holmes, Patrick; Knudsen, Søren Tang; Liutkus, Joanne; Sathyapalan, Thozhukat; Schultes, Bernd; Rudofsky, Gottfried Journal: BMJ open diabetes research and care Issue: Volume 10:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Issue 5 (21st February 2023) Authors: Aroda, Vanita R.; Erhan, Umut; Jelnes, Peter; Meier, Juris J.; Abildlund, Morten Tind; Pratley, Richard; Vilsbøll, Tina; Husain, Mansoor Journal: Diabetes, obesity & metabolism Issue: Volume 25:Issue 5(2023) Page Start: 1385 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗